Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1/2, Open-label Study Evaluating Safety of Repeat Administration of Ad/PNP-F-araAMP (Ad/PNP Administered Intratumorally Followed by Intravenous Fludarabine Phosphate) in Subjects With Recurrent, Local Head and Neck Cancer

Next Previous
Trial Profile

Phase 1/2, Open-label Study Evaluating Safety of Repeat Administration of Ad/PNP-F-araAMP (Ad/PNP Administered Intratumorally Followed by Intravenous Fludarabine Phosphate) in Subjects With Recurrent, Local Head and Neck Cancer

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 09 Jan 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Purine nucleoside phosphorylase (Primary) ; Fludarabine
  • Indications Head and neck cancer; Pharyngeal neoplasms; Salivary gland cancer; Squamous cell cancer; Tongue cancer
  • Focus Adverse reactions; Registrational
  • Sponsors GeoVax Labs

    • Most Recent Events

    • 04 Jan 2024 According to a GeoVax Labs media release, the company expect to complete the study by the third quarter of this year.
    • 04 Jan 2024 According to a GeoVax Labs media release, announced the closure of patient enrollment for the Phase 1/2 clinical study evaluating Gedeptin in patients suffering from advanced head and neck cancer.
    • 09 Nov 2023 According to a GeoVax Labs media release, the company is preparing to announce updates from this trial in the coming months
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top